Propofol: an immunomodulating agent
- PMID: 15899746
- DOI: 10.1592/phco.2005.25.5_part_2.28s
Propofol: an immunomodulating agent
Abstract
Propofol (2,6-diisopropylphenol) is a potent intravenous hypnotic agent widely administered for induction and maintenance of anesthesia and for sedation in the intensive care unit. Propofol is insoluble in water and therefore is formulated in a lipid emulsion. In addition, a preservative (ethylenediaminetetraacetic acid [EDTA] or sodium metabisulfite) is added to retard bacterial growth. Propofol has antiinflammatory properties, decreasing production of proinflammatory cytokines, altering expression of nitric oxide, and inhibiting neutrophil function. Propofol also is a potent antioxidant. The added preservatives have biologic activity; EDTA has antiinflammatory properties, whereas metabisulfite may cause lipid peroxidation. The antiinflammatory and antioxidant properties of propofol may have beneficial effects in patients with sepsis and systemic inflammatory response syndrome.
Similar articles
-
Free radical and drug oxidation products in an intensive care unit sedative: propofol with sulfite.Crit Care Med. 2003 Mar;31(3):787-92. doi: 10.1097/01.CCM.0000053560.05156.73. Crit Care Med. 2003. PMID: 12626985
-
Sulfite supported lipid peroxidation in propofol emulsions.Anesthesiology. 2002 Nov;97(5):1162-7. doi: 10.1097/00000542-200211000-00021. Anesthesiology. 2002. PMID: 12411802
-
Effects of propofol containing EDTA on mineral metabolism in medical ICU patients with pulmonary dysfunction.Intensive Care Med. 2000;26 Suppl 4:S422-32. doi: 10.1007/pl00003786. Intensive Care Med. 2000. PMID: 11310905 Clinical Trial.
-
The experimental and clinical pharmacology of propofol, an anesthetic agent with neuroprotective properties.CNS Neurosci Ther. 2008 Summer;14(2):95-106. doi: 10.1111/j.1527-3458.2008.00043.x. CNS Neurosci Ther. 2008. PMID: 18482023 Free PMC article. Review.
-
Propofol: therapeutic indications and side-effects.Curr Pharm Des. 2004;10(29):3639-49. doi: 10.2174/1381612043382846. Curr Pharm Des. 2004. PMID: 15579060 Review.
Cited by
-
Propofol Treatment Inhibits Constitutive Apoptosis in Human Primary Neutrophils and Granulocyte-Differentiated Human HL60 Cells.PLoS One. 2015 Jun 10;10(6):e0129693. doi: 10.1371/journal.pone.0129693. eCollection 2015. PLoS One. 2015. PMID: 26061531 Free PMC article.
-
NLRP1 Inflammasomes: A Potential Target for the Treatment of Several Types of Brain Injury.Front Immunol. 2022 May 30;13:863774. doi: 10.3389/fimmu.2022.863774. eCollection 2022. Front Immunol. 2022. PMID: 35707533 Free PMC article. Review.
-
Toll-Like Receptor Signaling Pathways: Novel Therapeutic Targets for Cerebrovascular Disorders.Int J Mol Sci. 2021 Jun 7;22(11):6153. doi: 10.3390/ijms22116153. Int J Mol Sci. 2021. PMID: 34200356 Free PMC article. Review.
-
Effect of propofol and sevoflurane on the inflammatory response of patients undergoing craniotomy.BMC Anesthesiol. 2016 Mar 22;16:18. doi: 10.1186/s12871-016-0182-5. BMC Anesthesiol. 2016. PMID: 27001425 Free PMC article. Clinical Trial.
-
Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions.Signal Transduct Target Ther. 2022 Jul 6;7(1):215. doi: 10.1038/s41392-022-01064-1. Signal Transduct Target Ther. 2022. PMID: 35794095 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical